文献速递生殖医学产科

复发性流产与支原体、脲原体感染:治疗后的前瞻性队列结局

Recurrent pregnancy loss and the role of Mycoplasma and Ureaplasma: a prospective cohort study with outcome after treatment.
PubMed 文献 · Fertil Steril · 2025-12-22

这项单中心前瞻性队列研究将1583例不明原因复发性流产患者与263例不孕对照按6:1匹配,检测宫颈支原体和脲原体感染并治疗阳性者及伴侣。复发性流产组支原体感染率4.2%、脲原体15.7%,均高于对照;治疗后超95%培养转阴,成功治愈者活产率分别为78%和76%,高于培养阴性者的64%。

要点

  • 复发性流产患者支原体感染率4.2%、脲原体15.7%,均显著高于不孕对照。
  • 多西环素治疗14天后超95%患者培养转阴。
  • 成功治愈者活产率78%(支原体)和76%(脲原体),高于培养阴性者64%。

核心结论

  • 支原体和脲原体可能参与复发性流产,成功根除后活产率高于对照患者。
  • 结果支持在复发性流产评估中考虑检测这些病原体,作为一种特异且微创的诊断方法。

研究设计与样本

  • 单中心前瞻性队列研究,复发性流产患者与不孕对照按6:1匹配。
  • 纳入1583例评估后无可识别原因的复发性流产患者和263例不孕对照。
  • 采用Fisher精确检验,研究效能设定为在95%置信水平检测培养阳性率和妊娠结局5%的差异。

主要发现

  • 复发性流产组支原体感染率4.2%(RR 10.9,CI 1.53-78.7),脲原体感染率15.7%(RR 1.59,CI 1.09-2.33);对照组分别为0.1%和9.89%。
  • 治疗后超过95%的患者达到培养转阴。
  • 成功治愈患者的活产率:支原体78%,脲原体76%,培养阴性复发性流产患者为64%。

关键数值与推荐

  • 所有患者接受高位宫颈管培养检测支原体和脲原体。
  • 阳性患者及伴侣接受14天多西环素治疗,随后进行治愈检测。
  • 初始治疗失败者使用替代抗生素。

临床怎么用

  • 在复发性流产评估中可考虑进行支原体和脲原体宫颈培养检测。
  • 检测阳性者及伴侣可接受多西环素治疗并复查治愈。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the prevalence of infectious etiologies such as Mycoplasma and Ureaplasma in a population experiencing recurrent pregnancy loss (RPL), assess live birth outcomes after treatment of these infections, and review the current literature on infectious workup for RPL. DESIGN: This single-center prospective cohort study matched RPL patients 6:1 with infertile controls. Fisher's exact test was used for statistical analysis, and the study was powered to detect a 5% difference in culture positivity and pregnancy outcomes at a 95% confidence level. SUBJECTS: The study included 1,583 patients with RPL with no identifiable cause after evaluation and 263 infertile controls. Patients with uncorrectable findings or loss of follow-up were excluded. EXPOSURE: All patients underwent testing for Mycoplasma and Ureaplasma using high-endocervical cultures. Positive cases and partners were treated with a 14-day course of doxycycline, followed by a test-of-cure. Alternative antibiotics were administered if initial therapy failed. MAIN OUTCOME MEASURES: Primary outcomes included infection rates of Mycoplasma and Ureaplasma. Secondary outcomes assessed treatment success and subsequent live birth rates in the RPL population. RESULTS: Recurrent pregnancy loss patients had higher infection rates of Mycoplasma (4.2%; relative risk [RR] 10.9, confidence interval [CI] 1.53-78.7) and Ureaplasma (15.7%; RR 1.59, CI 1.09-2.33) compared with controls (0.1% and 9.89%, respectively). Over 95% achieved negative test-of-cure cultures after treatment. Live birth rates were significantly higher in successfully treated patients: 78% for Mycoplasma and 76% for Ureaplasma, compared with 64% in culture-negative RPL cases. CONCLUSION: Mycoplasma and Ureaplasma may contribute to RPL, as successful eradication improved live birth rates compared with control patients. These findings support consideration of testing for these pathogens during RPL evaluations as a specific and minimally invasive diagnostic method.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Bishop S, Truong A, Jaslow C, et al. Recurrent pregnancy loss and the role of Mycoplasma and Ureaplasma: a prospective cohort study with outcome after treatment. Fertil Steril. 2025. PMID: 41443367. doi:10.1016/j.fertnstert.2025.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。